COVID-19 Pandemisi Sırasında Hipofraksiyone Meme Kanseri Işınlaması ve Erken Sonuçları; Tek Merkez Deneyimi

Hypofractionated Breast Cancer Irradiation and Early Results During the COVID-19 Pandemic; Single Center Experience

Özet

Amaç: COVID-19 pandemisi sırasında meme radyoterapisi uygulanan hastalarda hipofraksiyone radyoterapinin dozimetrik olarak analizi ve erken klinik sonuçlarının değerlendirilmesi amaçlanmıştır.

Abstract

Objective: We aimed to the dosimetric analysis of hypofractionated radiation therapy and early clinical results of patients who received breast radiation therapy during the COVID 19 pandemic. Materials and Methods: Seventeen women who received breast cancer radiotherapy were included in the study. For target volumes, the prescription dose was applied 42.55 Gray (Gy) in 16 fractions. COVID-19 symptoms and acute side effects of the patients were followed. Results: Seventeen breast cancer patients were treated with hypofractionated radiotherapy. Dose of 95% of target volumes and critical organ doses were evaluated by normalizing to 50 Gy in 25 fractions. When all plans were evaluated by normalizing to 50 Gy, the maximum dose of medulla spinalis was <45 Gy. The mean dose of heart was <5 Gy. The volume for the lung receiving 20 Gy or more was averaged 20.19. Grade 1 skin reaction was observed in only 5 patients during a mean follow-up of 5 months. Conclusion: In the treatment of breast cancer, hypofractionated radiotherapy is more suitable in terms of shortening the treatment period of patients in the pandemic period and being exposed to less risk. At the same time, the treatment cost is lower as the treatment time is shortened.